Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
1st human missions to Mars should hunt for signs of life, report says - 2The Extraordinary Excursion of Dental Embed Innovation
- 3My Pioneering Excursion: Building a Startup
- 4The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- 5The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- Supportive Tips On Home loans For First-Time Home Purchasers
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Vote In favor of Feasible Way You Prescribe to Shop for Garments
- Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- Astounding Treehouses All over the Planet
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
